Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

ISRG

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

ISRG

AI Research Report

Powered by Claude

Ready to analyze ISRG

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
JNJ
Johnson & Johnson
—
—
TMO
Thermo Fisher
—
—
WELL
Welltower
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Recent insider activity

View all →
  • 4PRIMARY DOCUMENT
    Mar 11
  • 4PRIMARY DOCUMENT
    Mar 10
  • 4PRIMARY DOCUMENT
    Mar 5
  • 4PRIMARY DOCUMENT
    Mar 3
  • 4PRIMARY DOCUMENT
    Mar 3
📅 Earnings in 7d (Apr 21)
Intuitive Surgical Inc

Intuitive Surgical Inc

Health Care·NASDAQ NMS - GLOBAL MARKET·US·IPO 2000-06-13
  • Yahoo·4h ago

    Assessing Intuitive Surgical (ISRG) Valuation After Strong Earnings And Growing Recurring Revenue

    Intuitive Surgical (ISRG) is back in focus after reporting quarterly EPS of 2.53 and revenue of US$2.87b on January 22, 2026. Both figures came in above expectations, prompting fresh attention on its growth profile. See our latest analysis for Intuitive Surgical. The latest quarterly beat and increased interest from major investors have come against a mixed backdrop, with a 1-day share price return of 1.85%, a 30-day share price return decline of 2.80%, and a 90-day share price return decline...

  • Yahoo·7h ago

    Johnson & Johnson Financial Chief Sees ‘Clear Line of Sight’ to Double-Digit Growth by 2030

    Johnson & Johnson has reinvented itself several times in recent years. Its latest earnings report signals the company has reinvented itself again. J&J posted adjusted earnings of $2.70 a share for the first quarter, narrowly beating out the $2.68 a share analysts had anticipated.

  • Benzinga·1d ago

    Mizuho Maintains Neutral on Intuitive Surgical, Lowers Price Target to $525

    Mizuho analyst Anthony Petrone maintains Intuitive Surgical (NASDAQ:ISRG) with a Neutral and lowers the price target from $575 to $525.

  • Yahoo·1d ago

    2 Cash-Producing Stocks Worth Your Attention and 1 We Brush Off

    Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

  • Yahoo·1d ago

    These 3 Stocks Have Crushed the Market, and the Next 10 Years Could Be Even Better

    Visa, Costco, and Intuitive Surgical are all positioned to keep winning.

  • Yahoo·4d ago

    Intuitive Surgical Inc. (ISRG): Israel Englander Is Loading Up on This Stock

    Intuitive Surgical, Inc. (NASDAQ:ISRG) is featured on the Israel Englander Stock Portfolio: Top 10 Stock Picks. Israel Englander has been a long-term admirer of Intuitive Surgical, Inc. (NASDAQ:ISRG) stock. The firm first made an appearance in the 13F portfolio of the fund in the fourth quarter of 2010. This holding comprised around 200,000 shares. After […]

  • Yahoo·4d ago

    ISRG Stock Down Nearly 20% YTD: Should You Buy, Hold or Sell?

    ISRG slides nearly 20% YTD despite strong procedure growth and upgrades, as valuation concerns and macro pressures weigh on near-term upside.

  • Benzinga·4d ago

    If You Invested $1000 In Intuitive Surgical Stock 10 Years Ago, You Would Have This Much Today

  • View all news →
NASDAQ NMS - GLOBAL MARKETAfter-hours
Intuitive Surgical Inc
Health Care
$467.22
$8.26 (+1.80%)
After-hrs · vs prev close $458.96
Open
$459.93
Prev close
$458.96
Day range
$459.50 – $471.24
52W range
$427.84 – $603.88
Mkt cap
$163.01B
P/E
56.1
EPS
$7.88
Beta
1.61

Analyst Consensus

Buy
Based on 41 analysts
Period: 2026-04-01
29 Buy (71%)11 Hold (27%)1 Sell (2%)
Rating Distribution
Strong Buy
11
Buy
18
Hold
11
Sell
1
Strong Sell
0
Trend
2026-04
29/11/1
2026-03
29/12/1
2026-02
29/12/1
2026-01
25/14/1

Fundamentals

Valuation
Market Cap
$163.01B
P/E (TTM)
56.14S&P avg ~22
P/S (TTM)
15.93S&P avg ~2.8
P/B
11.26S&P avg ~4.5
P/FCF
64.37S&P avg ~26
EPS (TTM)
$7.88
Book/sh
$50.19
Cash/sh
$17.00
Profitability
Gross Margin
66.00%avg ~45%
Operating Margin
29.27%avg ~15%
Net Margin
28.38%avg ~12%
ROE
16.36%avg ~18%
ROA
14.43%avg ~7%
ROI
16.36%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
20.51%
Rev Growth 5Y
18.22%
EPS Growth YoY
22.81%
EPS Growth 5Y
21.79%
Current Ratio
—
Quick Ratio
3.77
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.61
52W High
$603.88
52W Low
$427.84
Avg Vol (10D)
1.71M
Avg Vol (3M)
1.81M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (41)
Price Performance
5D+1.33%
MTD-0.44%
3M-21.56%
6M+2.06%
YTD-18.96%
1Y-6.24%

Factor Grades

View details →
B-
Overall score: 60/100
D-
Valuation
A-
Growth
A-
Profitability
D-
Momentum
A
Financial Health